GH administration decreases subcutaneous abdominal adipocyte size in men with abdominal obesity.

ABSTRACT:

Objective

To investigate the effects of short-term GH administration on abdominal subcutaneous adipocyte size and CT attenuation in men with abdominal obesity.

Design

6-week, randomized, double-blind, placebo-controlled study of GH (starting dose 2μg/kg/d) vs placebo of 15 abdominally obese men (mean age: 34±6years; mean BMI: 37.7±6.1kg/m², mean IGF-1 SDS: -1.9±0.5) who underwent abdominal subcutaneous adipose tissue (SAT) aspirations to determine adipocyte size, CTs for body composition and measures of glucose tolerance at baseline and 6weeks. GH dosing was titrated to target IGF-1 levels in the upper normal age-appropriate range.

Results

GH administration decreased subcutaneous abdominal adipocyte size compared to placebo. Adipocyte size was positively as

SUBMITTER: Bredella MA 

PROVIDER: S-EPMC5585040 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature